Top Markets
Coin of the day
ATyr Pharma, Inc. ATyr Pharma, Inc.

ATyr Pharma, Inc.

ATYR
Classificação em ações #25448
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego,... aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Preço da ação
$0.5049
Última sincronização: 2026-08-20
Valor de mercado
$49.51M
Variação (1 dia)
-5.24%
Variação (1 ano)
-89.80%
País
US
Negociar ATyr Pharma, Inc. (ATYR)

Categoria

Receita da ATyr Pharma, Inc. (ATYR)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da ATyr Pharma, Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da ATyr Pharma, Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH
$2.23B -
US